trending Market Intelligence /marketintelligence/en/news-insights/trending/5g2eKbGsHNxpj5HGBRKA3Q2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Genmab-J&J's Darzalex, chemotherapy combo approved in EU to treat blood cancer

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Genmab-J&J's Darzalex, chemotherapy combo approved in EU to treat blood cancer

The European Commission granted approval to Genmab A/S and Johnson & Johnson's Darzalex in combination with other medications to treat adult patients with a type of blood cancer.

Darzalex, or daratumumab, was approved in combination with chemotherapy drugs bortezomib and thalidomide plus corticosteroid medicine dexamethasone to treat adult patients with newly diagnosed multiple myeloma.

Multiple myeloma is cancer that forms in a type of white blood cell called a plasma cell. It causes cancer cells to accumulate in the bone marrow, where they crowd out healthy blood cells.

The approval follows a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use, or CHMP, in December 2019.

The therapy's approval was based on data from a late-stage study called Cassiopeia, which showed that the combination of Darzalex and chemotherapy was better than chemotherapy alone in treating multiple myeloma.

Genmab granted J&J an exclusive worldwide license to develop, manufacture and commercialize Darzalex in 2012.